Kiran Naqvi
Health Sciences Associate Clinical Professor, Division of Hematology/Oncology, Department of Medicine
Biography
Kiran Naqvi, M.D., M.P.H., is Health Sciences Associate Clinical Professor in the Division of Hematology/Oncology, Department of Medicine at the University of California, Irvine. Naqvi received a Bachelor of Medicine and Surgery from Dow Medical College and Civil Hospital at the University of Karachi, Pakistan, and completed a Masters in Public Health from The University of Texas School of Public Health. Prior to joining UC Irvine in 2022, Naqvi served as Assistant Professor and Section Head of Chronic Myeloid Leukemia in the Department of Leukemia at the University of Texas M.D. Anderson Cancer Center, and as Medical Director for Venetoclax Myeloid and Multiple Myeloma Product Development at Genentech.
Naqvi's clinical and research work focuses on myeloid malignancies, particularly chronic myeloid leukemia, acute myeloid leukemia, and myelodysplastic syndromes. Naqvi has served as principal investigator on multiple clinical trials evaluating novel therapeutic approaches, including studies of lower-dose dasatinib as frontline therapy for chronic myeloid leukemia and venetoclax-based combinations in myelodysplastic syndromes. Naqvi's research has examined the impact of comorbidities on outcomes in myelodysplastic syndromes and the role of clonal hematopoiesis mutations in disease prognosis.
Naqvi has authored or co-authored over 65 peer-reviewed publications and served as a reviewer for Clinical Lymphoma, Myeloma and Leukemia. Naqvi is a member of the American Society of Hematology, American Society of Clinical Oncology, and European Hematology Association, and contributed to the National Comprehensive Cancer Network Clinical Practice Guidelines for Chronic Myeloid Leukemia. At UC Irvine, Naqvi provides clinical education to hematology/oncology fellows through team-based teaching, clinic supervision, and didactic sessions.
Return to topEducation
- MBBS, University of Karachi, Dow Medical College and Civil Hospital, 2001
- MPH, The University of Texas School of Public Health, 2012
Distinctions
- Kimberly Patterson Fellowship in Leukemia Research, M. D. Anderson Cancer Center, 2011
- Professionalism Award, Internal Medicine Residency Program, University of Illinois, 2005
- Honors in Biochemistry, Dow Medical College and Civil Hospital, 1998
- Honors in Surgery and Ophthalmology, Dow Medical College and Civil Hospital, 2001
Areas of Expertise
- Hematologic Malignancies
- Chronic Myeloid Leukemia Therapy
- Myelodysplastic Syndrome Prognostication
- Tyrosine Kinase Inhibitor Dosing
- Venetoclax Combination Regimens
- FLT3 Inhibitor Development
- Clonal Hematopoiesis Comorbidity Impact
Recent Publications
- Lee B.J., Griffin S.P., Doh J., Quach A., Sun Y., Chumnumsiriwath P., Ciurea S.O., Ramos-Perez J., Bellman P., Jeyakumar D., Kongtim P., Naqvi K., “Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia” (opens in new tab), British Journal of Haematology, vol. 208, pp. 570-578, 2026.
- Xiao J., Kim J., Park B., Baylink D.J., Kwon C., Tran V., Lee S., Codorniz K., Tan L., Moreno P.L., Schill-Depew A., Mirshahidi S., De Semir D., Hanna D., Naqvi K., Cao H., Chen C.-S., Xiu J., Lenz H.-J., Mirshahidi H., et al., “Targeting DNA helicase CMG complex and NFκB2-driven drug-resistant transcriptional axis to effectively treat KRASG12D-mutated pancreatic cancer” (opens in new tab), Experimental Hematology and Oncology, vol. 14, 2025.
- Lee BJ, Griffin SP, Doh J, Chan A, Ciurea SO, Jeyakumar D, Fleischman AG, Naqvi K, Pannunzio NR, O'Brien S, Kongtim P, “HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia” (opens in new tab), European Journal of Haematology, vol. 112, no. 3, pp. 392-401, 2024.
- DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, et al., “Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses” (opens in new tab), Nature Cancer, vol. 5, no. 10, pp. 1515-1533, 2024.
- Lee BJ, Griffin SP, Doh J, Ciurea SO, Jeyakumar D, Kongtim P, Naqvi K, “Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience” (opens in new tab), Annals of Hematology, vol. 103, no. 12, pp. 5395-5403, 2024.
- Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie R, Odenike O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng WH, Zhou Y, Hoffman D, Harb JG, Potluri J, Garcia-Manero G, “A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes” (opens in new tab), American Journal of Hematology, vol. 98, no. 2, pp. 272-281, 2023.
- Gershon A, Ma E, Xu T, Montez M, Naqvi K, Ku G, Cheng WW, Flahavan EM, Kota V, Greenwald DR, “Early real-world first-line treatment with Venetoclax plus HMAs versus HMA monotherapy among patients with AML in a predominantly US community setting” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 23, no. 5, pp. e222-e231, 2023.
- Senapati J, Muftuoglu M, Ishizawa J, Abbas HA, Loghavi S, Borthakur G, Yilmaz M, Issa GC, Dara SI, Basyal M, Li L, Naqvi K, Pourebrahim R, Jabbour EJ, Kornblau SM, Short NJ, Pemmaraju N, Garcia-Manero G, Ravandi F, Khoury J, et al., “A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine with or without venetoclax in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis” (opens in new tab), Blood Cancer Journal, vol. 13, no. 1, pp. 101, 2023.
- Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Brackman D, Siddani S, Wang J, Chyla B, Lee P, Altman JK, “Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia” (opens in new tab), Journal of Clinical Oncology, vol. 40, no. 35, pp. 4048-4059, 2022.
- Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, et al., “Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens” (opens in new tab), Haematologica, vol. 106, no. 3, pp. 894-898, 2021.
Most Cited Publications
- Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME, “Association of Comorbidities with Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model” (opens in new tab), Journal of Clinical Oncology, vol. 29, no. 16, pp. 2240-6, 2011.
- Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM, “Long-term follow-up of lower dose dasatinib (50mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia” (opens in new tab), Cancer, vol. 126, no. 1, pp. 67-75, 2020.
- Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Ravandi F, Faderl S, Kantarjian H, Garcia-Manero G, “Implications of Discrepancy in Diagnosis of Myelodysplastic Syndrome Between Referral and Tertiary Care Centers” (opens in new tab), Blood, vol. 118, no. 17, pp. 4690-3, 2011.
- Khan M, Siddiqi R, Naqvi K, “An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)” (opens in new tab), Annals of Hematology, vol. 97, no. 6, pp. 945-953, 2018.
- Maiti A, Naqvi K, Kadia TM, Borthakur G, Takahashi K, Bose P, Daver NG, Patel A, Alvarado Y, Ohanian M, DiNardo CD, Cortes JE, Jabbour EJ, Garcia-Manero G, Kantarjian HM, Ravandi F, “Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 19, no. 3, pp. 142-148.e1, 2019.
- Daver N, Naqvi K, Jabbour E, Kadia T, DiNardo C, Cardenas-Turanzas M, Pierce S, Nguyen KT, Bueso-Ramos C, Kantarjian H, Garcia-Manero G, “Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes” (opens in new tab), American Journal of Hematology, vol. 89, no. 5, pp. 509-16, 2014.
- Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S, “Comorbidities predict worse prognosis in patients with primary myelofibrosis” (opens in new tab), Cancer, vol. 120, no. 19, pp. 2996-3002, 2014.
- Naqvi K, Ravandi F, “FLT3 inhibitor Quizartinib (AC220)” (opens in new tab), Leukemia and Lymphoma, vol. 60, no. 8, pp. 1866-1876, 2019.
- Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G, “Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome” (opens in new tab), Cancer, vol. 125, no. 13, pp. 2233-2241, 2019.
- Naqvi K, Konopleva M, Ravandi F, “Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199” (opens in new tab), Expert Review of Hematology, vol. 10, no. 10, pp. 863-874, 2017.
This profile was created with the help of AI.
Last updated on 8/7/2026.